| Eligibility |
Inclusion Criteria:
1. The histopathologically confirmed metastasis is adenocarcinoma, squamous cell
carcinoma, poorly differentiated carcinoma, poorly differentiated malignant tumor or
neuroendocrine carcinoma;
2. Patients whose primary lesions cannot be found after standard evaluation prior to
treatment: detailed history, physical examination, blood test, chest and pelvic CT,
PET/CT (optional), endoscopy of symptomatic sites, and pathological examination;
3. Measurable lesions (RECIST 1.1 criteria);
4. Patients who have progressed after receiving first-line treatment for Carcinoma of
Unknown Primary. For example, those who have received paclitaxel or docetaxel in the
first-line treatment and progressed more than three months after the end of last
treatment;
5. ECOG of 0-2;
6. Life expectancy>3 months;
7. Within 7 days (including 7 days) before screening, the laboratory test data
requirements: neutrophil count =1.5×10^9/L, platelet count =90×10^9/L, hemoglobin
=90g/L (No blood transfusion in 14 days), serum total bilirubin =1.25 times the upper
limit of normal (ULN); ALT and AST=2.5 x ULN (patients with liver metastases =5x ULN);
serum creatinine =1.25 x ULN
Exclusion Criteria:
1. Patients who have previously been treated with albumin paclitaxel or bevacizumab or
PD-1 monoclonal antibody;
2. Received any experimental drugs or anti-tumor drugs within 4 weeks prior to
enrollment;
3. A history of other tumors in the past 5 years, except for cervix or basal cell
carcinoma of the skin that has been cured;
4. Symptomatic brain or meningeal metastases (unless the patient receives treatment for>
6 months, the imaging results are negative within 4 weeks before entering the study,
and the clinical symptoms related to the tumor are stable at the time of entering the
study).
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
|
